Clinical data | |
---|---|
Pronunciation | ahr-tez′ŭ-nāt[1] |
Trade names | many[2] |
Other names | SM-804 |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
License data |
|
Routes of administration | By mouth, intravenous, intramuscular |
Drug class | Artemisinin |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number |
|
PubChem CID | |
DrugBank |
|
ChemSpider | |
UNII |
|
KEGG | |
ChEBI | |
ChEMBL |
|
NIAID ChemDB | |
PDB ligand | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.106.898 |
Chemical and physical data | |
Formula | C19H28O8 |
Molar mass | 384.425 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Artesunate (AS) is a medication used to treat malaria.[3][5][6] The intravenous form is preferred to quinine for severe malaria.[5] Often it is used as part of combination therapy, such as artesunate plus mefloquine.[6] It is not used for the prevention of malaria.[6] Artesunate can be given by injection into a vein, injection into a muscle, by mouth, and by rectum.[6][7][8]
The most common side effects include kidney failure requiring dialysis, hemoglobinuria (the presence of hemoglobin in urine) and jaundice.[9]
Artesunate is generally well tolerated.[7] Side effects may include a slow heartbeat, allergic reaction, dizziness, and low white blood cell levels.[6] During pregnancy it appears to be a safer option, even though animal studies have found harm to the baby.[10] Use is likely fine during breastfeeding.[11] It is in the artemisinin class of medication.[5]
Artesunate was developed by Liu Xu in 1977.[12] It is on the World Health Organization's List of Essential Medicines.[13] It was approved for medical use in the United States in May 2020.[14] It is in the class of medications known as artemisinins, which are derivatives from "qinghao," or sweet wormwood plant (Artemisia annua).[15][5]
FDA snapshot
was invoked but never defined (see the help page).FDA PR
was invoked but never defined (see the help page).